Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Lysophosphatidic acid (LPA) is a bioactive lipid mediator that signals through five distinct G protein-coupled receptors (LPA1-5). Ki16425 is a LPA receptor antagonist with selectivity for LPA1 and LPA3. It exhibits Ki values of 0.34, 6.5, and 0.93 µM for the human LPA1, LPA2, and LPA3 receptors, respectively, as determined by measuring inositol phosphate production in RH7777-transfected cells. Ki1642, at 10 µM, significantly blocks the response of a variety of cancer cell lines to LPA-induced cell migration.
Ki16425 is supplied as a crystalline solid. A stock solution may be made by dissolving the Ki16425 in an organic solvent purged with an inert gas. Ki16425 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of Ki16425 in these solvents is approximately 10 mg/ml. Ki16425 is sparingly soluble in aqueous buffers. Ki16425 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ki16425 has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Choi, J.W., Lee, C.-W., and Chun, J. Biological roles of lysophospholipid receptors revealed by genetic null mice: An update. Biochim. Biophys. Acta 1781, 531-539 (2008)
Ohta, H., Sato, K., Murata, N., et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol. Pharmacol. 64(4), 994-1005 (2003).
Yamada, T., Sato, K., Komachi, M., et al. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA. J. Biol. Chem. 279(8), 6595-6605 (2004).